Objective: The prognostic value of metabolic parameters using 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has not been established for early non-small cell lung cancer (NSCLC). Accordingly, the authors investigated the prognostic value of metabolic parameters in terms of failure patterns in patients with early NSCLC who underwent stereotactic body radiation therapy (SBRT). Methods: Data from 35 patients with Stage I NSCLC who underwent SBRT using CyberKnife and received pretreatment FDG PET/CT between 2008 and 2016 were retrospectively reviewed. Maximum standardized uptake value (SUVmax), metabolic tumor volume, and total lesion glycolysis were measured. The significance of these parameters with regard to failure patterns was assessed.
Introduction
Ablative irradiation, particularly stereotactic body radiation therapy (SBRT), is an effective primary treatment for patients with early stage non-small-cell lung cancer (NSCLC) who are medically inoperable or refuse surgery. Over the past decades, previous studies have reported that local control following SBRT reached~90%, with low acute and chronic toxicity (1, 2) . Moreover, some studies focused on operable patients, and reported excellent local control and survival (3, 4) .
In general, SBRT has been performed on patients with early local disease who did not require systemic treatment throughout the intensive staging work-up, as determined by specialist opinion through a multidisciplinary approach. However, in patients who received SBRT, we often observed non-local failure (LF), including regional failure (RF) and/or distant failure (DF) even in the absence of LF. A previous study reported that the predominant pattern of failure in patients treated with definitive radiotherapy (RT), including conventional RT and SBRT, is the development of distant metastasis (5) , suggesting that such patients require the addition of adjuvant treatment. The investigation of features associated with high risk for non-LF is important for determining an appropriate treatment approach (6) .
Recently, 18 F-fluorodeoxyglucose positron emission tomography/ computed tomography (FDG PET/CT) has become mandatory in the initial staging evaluation for various malignancies, including NSCLC. Metabolic parameters related to FDG uptake within tumors represent clinical tumor burden and aggressiveness (7, 8) . Accordingly, the potential prognostic value of metabolic quantitative FDG PET/CT parameters in pretreatment evaluation has been reported for a variety of malignant tumors (7, 9, 10) . Recently, investigations examining the relationship between the metabolic parameters of PET/CT and prognosis in early NSCLC with regard to SBRT has been reported owing to SBRT has been extensively applied to early lung cancer (5, 11, 12) .
Thus, the present study aimed to determine the clinical significance and predictive value of metabolic FDG PET parameters and patterns of failure in early NSCLC treated with robotic SBRT.
Patients and methods

Patient selection
Between July 2008 and February 2016, 41 consecutive patients (41 lesions) with pathologically proven early NSCLC (T1-2aN0M0) who were treated with SBRT using CyberKnife as primary treatment alone were retrospectively identified. Of these patients, six were excluded from this study because they did not undergo a pretreatment FDG PET/CT scan for initial staging. Ultimately, a total of 35 patients were analyzed in the present study. Patients were referred to the CyberKnife Center as an alternative to the surgical approach for the following reasons: lack of adequate respiratory reserve; cardiac dysfunction due to heart disease; low performance status; or refused surgery. The present study was approved by the Institutional Review Board of the authors' institution.
FDG-PET method and measurements of metabolic parameters
All patients fasted for a minimum of 6 h, and blood glucose level was controlled to a level <180 mg/dl (3.3 mmol/l) before FDG-PET/ CT scan. Generally, patients received an intravenous injection of FDG in the arm contralateral to the primary tumor. All patients were studied in the supine position with their arms raised, and PET/ CT scans were performed on a PET/CT scanner (Discovery PET/CT 690 and a 64-slice CT, GE Healthcare, Waukesha, WI, USA) and a Biograph Duo (Siemens Medical Solutions USA, Inc., Knoxville, TN, USA). At 60 min after injection of FDG, whole-body emission scans were acquired using a PET camera. We did not yet use a respiratory gating system during scan although respiratory gated acquisition has been attributed to significant improvement on PET quantification, such as the maximum standard uptake value (SUVmax) (13, 14) . The CT attenuation correction acquisition parameters for the GE scanner were as follows: voltage, 120 kV; tube current, 140 mA; and slice thickness, 3.75 mm. Parameter settings for the Siemens device were: voltage, 130 kV; CARE Dose 4D mA tube current; and slice thickness, 5.00 mm. PET data were acquired using 2 min/bed position with a 128 × 128 matrix. Images were reconstructed using an iterative reconstruction algorithm. All PET images were corrected for attenuation using the acquired CT data.
All FDG PET/CT images for initial staging were reviewed by an experienced nuclear medicine physician (M.K. Lee), who measured SUVmax, MTV and total lesion glycolysis (TLG). SUVs were calculated using the following equation: SUV tissue radio activity Bq /tissue weight g injected activity Bq /body weight g .
The highest SUV in the primary lesion of each patient was defined as the SUVmax, which was calculated by measuring the absorption of FDG by tumors in the region of interest. The volumetric parameter MTV was defined as the total tumor volume segmented via optimal threshold SUV. In the present study, threshold SUVs were adopted from a fixed SUV value of 2.5, which has been widely used for NSCLC according to previous reports (15, 16) . TLG was calculated by multiplying MTV by the mean SUV in the MTV, and represented the sum of SUVs within the tumor.
SBRT
All patients elected to undergo SBRT using CyberKnife (Accuray, Inc., Sunnyvale, CA, USA) in a multidisciplinary approach, which included a participating medical oncologist, a radiation oncologist, a thoracic surgeon, a pathologist, a nuclear medicine physician, and a radiologist. For SBRT, the thoracic radiologist placed 1 to 2 gold fiducials in and around the tumor using CT guidance. Thin-slice CT planning (1 mm contiguous axial slices) with contrast for SBRT was performed 7-10 days after this procedure. Subsequently, SBRT was delivered using a real-time target-tracking technique, which was achieved by radiographic detection of the fiducial marker along with respiratory motion. For SBRT, the gross tumor volume (GTV) was delineated in contrast-enhanced images, and the clinical target volume (CTV) was generated from the GTV by adding a margin according to histology and microscopic disease extension: 6 mm margin for squamous cell carcinoma, and 7 mm margin for adenocarcinoma. The planning target volume (PTV) 1 was then defined as GTV plus a 3 mm margin, and PTV 2 as CTV plus a 3 mm margin (Fig. 1) . The prescription of total dose and fractionation for PTV was decided according to physician discretion, considering not only institutional protocol (Table 1) , but also lung function and tumor location. Our institutional SBRT prescription was based on tumor size and/or tumor volume regarding pulmonary toxicity, but it was maintained above biologically effective dose (BED) 100 Gy (17) (18) (19) . The total dose enclosed 100% of the GTV, and each prescription dose enclosed >95% of each PTV. In other words, PTV 2 covered >95% on the basis of three-quarters of the total dose.
Pattern failure assessment and statistical analysis
In general, patients were assessed 3 months after treatment using contrast-enhanced CT of the chest and abdomen, or PET/CT for the first 12 months after completion of SBRT, and every 6 months thereafter to evaluate progression. In addition, bone scintigraphy, brain magnetic resonance imaging and pulmonary function tests were performed to assess suspected progression according to symptoms. During follow up, patterns of failure were observed, and defined and categorized as follows: LF (progression within ipsilateral lung); RF (progression in the regional lymph node [LN] area); DF (progression in the contralateral lung, other distant organs or non-regional LN metastasis).
The time to failure, including LF, RF and DF, was calculated from the date of diagnosis until the date of progression. In addition, progression-free survival (PFS) was calculated from the date of diagnosis to the date of disease progression, date of death due to any cause, or last follow-up visit. Overall survival (OS) was calculated from the date of initial diagnosis to the date of last follow-up or death from any cause. The LF, RF, and DF rates, PFS, and OS were estimated using the Kaplan-Meier method. Univariate analysis of risk factors was performed by comparing failure rates using the log-rank test. P < 0.05 was considered to be statistically significant. All analyses were performed using SPSS version 20.0 (IBM Corporation, Armonk, NY, USA).
Results
Baseline characteristics
Of the 35 patients in this study, 20 (57.1%) were male and 15 (42.9%) were female, with a median age of 75 years (range, 60-89 years). Eleven patients were T1aN0, 9 were T1bN0, and 15 were T2aN0. Adenocarcinoma was the dominant (54%) histological type. Among the 35 lesions, the mean (±standard deviation [SD]) volume of tumor was 19 ± 19 ml (range, 2-87 ml). With respect to metabolic parameters of PET/CT, the mean (±SD) SUVmax, MTV and TLG were 8.1 ± 5.1, 12.8 ± 16.9 ml and 72.9 ± 115.5, respectively. Total doses of SBRT ranged from 45 to 60 Gy, delivered in 3-5 fractions. Clinical characteristics of the patients, tumors and SBRT are summarized in Table 2 .
Patterns of failure
The median follow-up was 23 months (range, 3-77 months) for all patients and 34 months (range, 3-77 months) for living patients. Ten (29%) patients experienced progression: 3 LF, 5 RF and 8 DF. Of 10 patients who experienced progression, 7 (20%) had non-LF without LF. Details of the failure patterns are presented in Table 3 .
The three-year local, regional and distant control rates were 96.7%, 86.4% and 71.1%, respectively. No clinical factor was DLCO, carbon monoxide diffusing capacity; FEV1, forced expiratory volume in one second; SCCa, squamous cell carcinoma; Adenoca, adenocarcinoma; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; SBRT, stereotactic body radiation therapy; Gy, gray; BED, biologically effective dose; RT, radiotherapy; SD, standard deviation.
determined to be a significant prognosticator affecting LF, whereas only TLG (<73 vs. ≥73, P = 0.037) showed a significant association with LF. Both SUVmax (<9 vs. ≥9, P = 0.093) and MTV (<13 vs. ≥13 ml, P = 0.065) showed a borderline significant association with to LF (Table 4 ). In terms of RF, high SUVmax (<9 vs. ≥9) was an independent predictive factor associated with increased RF (P = 0.027, Fig. 2A ). However, neither MTV (<13 vs. ≥13 ml, P = 0.937) nor TLG (<73 vs. ≥73, P = 0.299) affected RF. Moreover, other clinical factors related to RF, including T stage (T1 vs. T2, P = 0.141), sex (male vs. female, P = 0.315), pathology (adenocarcinoma vs. others, P = 0.530), and BED (<140 vs. ≥140 Gy, P = 0.502) did not demonstrate statistical significance.
Sites of DF included the contralateral lung (n = 2), pleura (n = 1), and bone (n = 5). Among the metabolic factors of PET, only high SUVmax (<9 vs. ≥9) was associated with increased DF (P = 0.008, Fig. 2B ). T stage (T1 vs. T2) demonstrated borderline significance affecting DF (P = 0.077), whereas no significant difference of DF was observed with regard to sex (male vs. female, P = 0.475), pathology (adenocarcinoma vs. others, P = 0.866), and BED (<140 vs. ≥140 Gy, P = 0.482). All specific analyses of prognostic factors affecting LF, RF and DF are shown in Table 4 .
Survival outcomes
During follow-up, 13 patients died and 22 patients were alive. Three-year PFS and OS were 55% and 61%, respectively. Only high SUVmax was identified as a significant factor associated with decreased PFS (P = 0.015, Fig. 3A ) and OS (P = 0.034, Fig. 3B ).
Other clinical and metabolic parameters were not significant prognostic factors affecting these survivals (Table 4) .
Toxicity
During or shortly after SBRT, no patients developed toxicities associated with SBRT. Thereafter, during the follow-up period, 10 patients had Grade 1 radiation pneumonitis (RP), and two had Grade 2 RP, both of whom achieved symptomatic relief with conservative management and the use of steroid agents.
Discussion
This study was conducted to determine the prognostic value of metabolic parameters of FDG PET/CT in patients with early NSCLC, who were treated with SBRT using Cyberknife. Our findings demonstrated that patients diagnosed with early NSCLC with high SUVmax (≥9) were at a statistically significant higher risk for both RF and DF than those with lower SUVmax (<9), and that SUVmax also reduced PFS and OS. Additionally, pre-SBRT high SUVmax may serve as a prognosticator for identifying patients who are at increased risk of failure or death and who could be a candidate for adjuvant therapy after SBRT.
There are several reports of the prognostic value of PET parameters for Stage I NSCLC cohorts treated with surgical resection (20) (21) (22) (23) . Ohtsuka et al. reported that FDG uptake appeared to be predictive of disease-free survival in patients with Stage I lung adenocarcinoma who received surgical resection (20) . Goodgame et al. reported that high SUVmax (≥5.5) on preoperative FDG PET is an independent predictor of relapse and death in Stage I operated NSCLC (22) . A recent systematic review by the International Association for the Study of Lung Cancer also suggested that PET SUV has prognostic value in NSCLC (23) . Other studies have reported that early NSCLC with high PET factors, including SUVmax, are poor prognostic factors, and may prompt the consideration of additional therapy, similar to other prognostic factors such as tumor size, lymphovascular invasion and histological differentiation (24, 25) . Several studies of RT have also demonstrated the relationship between PET parameters and prognosis of patients with early NSCLC treated with SBRT (8, 11, 12) . A previous study involving 163 patients who were diagnosed with T1/2N0 NSCLC and received definitive RT reported that early NSCLC with SUVmax > 7 was associated with decreased regional recurrence-free survival and distant metastasis-free survival (5). Furthermore, Clarke et al. adenoca, adenocarcinoma; UL, upper lobe; ML, middle lobe; LL, lower lobe; T, tumor; SBRT, stereotactic body radiation therapy; BED, biologically effective dose; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis.
*Log-rank P value.
reported that SUVmax with a cut-off of ≥5 on baseline FDG PET/ CT before SBRT correlated a higher risk of DF and poorer RFS (12) . Consistent with these previous studies, we found that clinical outcomes of early NSCLC patients with higher SUVmax (≥9) who were treated with SBRT were less favorable than those with lower SUVmax (<9). However, another study reported that pretreatment PET SUVmax did not predict RF, DF, or OS in patients treated with SBRT for early-stage NSCLC (11) . Future trials should investigate whether PET parameters, including SUVmax, are predictors of the prognosis of patients with early NSCLC receiving SBRT. This will help clarify whether patients with early NSCLC and tumors with high PET parameter values should undergo adjuvant therapy for improved outcomes. Many researchers have suggested that the association between SUVmax and prognosis originates from the aggressive biology of tissues with high SUVmax (10, 20) . A study from the Memorial Sloan-Kettering Cancer Center demonstrated that SUVmax value was correlated with histological grade and mitotic count, although this investigation focused primarily on adenocarcinoma (10) . Additionally, a Japanese multicenter study demonstrated that higher SUVmax reflected aggressive behavior in clinical T1N0M0 adenocarcinomas, regardless of other clinical factors (6) . Furthermore, Nair et al. observed that FDG uptake features of SUV were associated with oncogenomic alteration affecting survival (8) . Overall, these results suggested that early NSCLC with high SUVmax had a high propensity for dissemination, resulting from undetectable hematogenous and lymphatic spread. Additionally, a previous study reported that SUVmax was a strong predictor which showed increased aggressiveness as T stage, N stage and M stage were increase (26) . SUVmax may be a biomarker reflecting the aggressive properties of a tumor, which could facilitate risk stratification in early NSCLC. Generally, SUVmax is understood as a single metabolic value of a measured tumor, whereas MTV and TLG are volumetric values representing the entire metabolic and volumetric burden of the tumor. Previous studies have investigated volumetric indices to understand the reliability of integrated information associated with tumor burden and aggressiveness over T staging (27, 28) . In our study, while SUVmax demonstrated clinical significance as a prognosticator related to RF, DF and survival, TLG as volumetric parameter was shown to have a significant effect on LF, which may be the result of a high tumoral and peri-tumoral burden associated with high TLG, rather than tumor aggressiveness. Therefore, it might be suggested that tumors with high TLG require a delineation of target volume, with a relatively generous margin for primary limited lesion such as staged T1-2N0M0.
Age, sex, histological cell type and pathological TNM stage are known to be important factors in NSCLC (24) . Thus, patients are initially diagnosed according to physical examination, laboratory results, pathology review, and chest CT and upper abdomen CT, including the adrenal glands. For some clinicians, PET metabolic parameters may be considered as only a supplementary modality to the current work-up staging system, which adds a metabolic variable to the tumor staging system. However, it has been reported that the diagnostic value of PET-CT for the pretreatment staging of NSCLC was superior to that of CT scans (26, 29, 30) . A study showed that FDG-PET SUVmax of the primary tumor was a statistically significant predictor of pathological nodal involvement in clinical N0 NSCLC, reporting that 51% of patients with NSCLC with an SUVmax ≥ 10 had pathological node-positive disease, while 13% of the remaining patients with an SUVmax < 10 had nodal disease (31) . Another study reported that SUVmax is a more powerful predictor for both recurrence and survival than TNM stage in NSCLC (26) . Accordingly, in the current study, the TNM classification (T1 vs. T2) did not demonstrate differences in failure and survival, whereas there was a significant difference in failure and survival based on SUVmax (<9 vs. ≥9). It should be noted, however, that these TNM stages were inferred from clinical status. We eventually confirmed the importance of PET metabolic parameters in terms of the staging work-up process, which provided useful information about prognosis, particularly in early NSCLC (9, 32) .
The limitations of this study include the retrospective nature and the relatively short follow-up period. Additionally, the small number of patients corresponds to limited inclusiveness and low statistical power. Larger-scale prospective studies are needed to confirm the prognostic value of FDG PET/CT metabolic parameters in patients with early NSCLC who are treated with SBRT. Moreover, there is a lack of standardized criteria for determining SUVmax specific to early NSCLC because optimal cut-off values have not been established, despite SUVmax being reported as less subjective and more reproducible than other PET parameters (32) . The need for the determination of an optimal threshold value of SUVmax for early NSCLC has also described in a previous systemic review (21) .
In conclusion, SUVmax independently predicted the likelihood of metastasis to both regional and distant sites in early stage NSCLC treated with SBRT. Based on our findings, SUVmax can be used to stratify early NSCLC according to risk for RF and/or DF, which may facilitate the selection of patients who require adjuvant treatment. Subsequently, these tailored treatments could potentially improve the outcomes of early NSCLC in patients with heterogeneous prognosis.
